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Decreased plasma levels of activated factor 




Background: The initiating trigger in the development of deep vein thrombosis (DVT) 
remains unidentified. It has been suggested that tissue factor-bearing microparticles play a 
key-role, which indicate a role for the tissue factor (TF)-pathway in the initiation of DVT. 
Objective: To assess the role of the TF-pathway in the initiation of venous thrombosis, we 
measured plasma levels of factor VII and VIIa in patients with acute DVT and in controls. 
Methods: we included 148 patients diagnosed with acute DVT and 179 controls in this 
study. Antigen levels of FVII and FVIIa were measured using assays recently developed in 
our laboratory. Results: Median FVII levels in patients were 109.8% (interquartile range 
[IQR] 86.0-153.2) compared with 102.2% (IQR 76.1-141.7) in controls. Individuals 
with FVII levels in the upper quartile had a 1.6-fold increased risk for the presence of a 
DVT (odds ratio 1.6, 95% confidence interval 0.8-3.1). Median FVIIa levels in patients 
were 50.2 ng/ml (IQR 25.2-86.1) compared with 96.6 ng/ml (IQR 69.9-168.9) in 
controls. Individuals with FVIIa levels in the lowest quartile had a more than 5-fold 
increased risk for the presence of a DVT (odds ratio 5.5, 95% confidence interval 2.8-
10.6). Both risks did not change substantially after adjustment for potential confounders. 
Conclusion: Decreased plasma levels of FVIIa in patients with deep vein thrombosis may 






Venous thrombosis is a multi-causal disease for which many genetic and acquired risk 
factors have been firmly established (reviewed in [1]). These risk factors generally increase 
hemostatic potential by either enhancing activation of coagulation or by decreasing 
inhibition of coagulation [2]. In addition, a hypofibrinolytic status has been repeatedly 
shown to increase the risk for venous thrombosis [3-5]. Although it is clear that alterations 
in the hemostatic balance may contribute to the development of venous thrombosis, 
the initiating trigger remains unidentified. In contrast to arterial thrombosis, in which 
exposure of thrombogenic material present in atherosclerotic plaques initiates thrombus 
formation, such lesions are absent in veins. Remarkably, the endothelial lining of a 
thrombosed vein appears to be intact, suggesting that initiation of thrombus formation 
proceeds via components present within the bloodstream [6,7]. It has been suggested that 
tissue factor (TF)-bearing microparticles present in the circulation play a key-role in the 
initiating of deep vein thrombosis (DVT) [8-12]. It has been proposed that activation 
of the venous endothelial lining, for example by venous stasis, leads to the recruitment 
of TF-bearing microparticles via P-selectin expressed on the activated endothelium and 
P-selectin glycoprotein ligand-1 (PSGL-1) on the TF-bearing microparticles. This process 
results in accumulation of TF, which, possibly after fusion with platelets or endothelial 
cells, initiates venous thrombus formation [13]. Because high plasma levels of FVII 
and low levels of TFPI are risk factors of venous thrombosis [14,15], a role of the TF 
pathway in the initiation of coagulation during venous thrombosis is plausible. Recently, 
however, a clinical study suggested a pivotal role for the intrinsic pathway in venous 
thrombosis. A novel anticoagulant strategy using antisense nucleotides toward FXI was 
effective in venous thrombosis prevention after knee replacement surgery [16]. It has, 
however, not yet been established whether this central role of FXI in venous thrombosis 
relates to FXIIa- or thrombin-mediated activation of FXI. It is tempting to speculate that 
thrombin-mediated activation of FXI is the dominant mechanism because elevated FXI 
levels are a risk factor for venous thrombosis [17], whereas FXII levels are not associated 
with venous thrombosis risk [18]. The latter scenario, again, is compatible with the TF 
pathway as the initiator of venous thrombus formation. To assess the contribution of 
TF in the initiation of venous thrombosis, we measured plasma levels of factor VII and 
VIIa in patients with acute DVT and in controls. Because TF-mediated activation of 
coagulation starts with the conversion of zymogen to activated FVII, we hypothesized 
that there would be increased plasma levels of FVIIa in patients with DVT, which would 





The study design was described earlier [19]. In short, patients (≥18 years old) with 
suspicion of acute symptomatic DVT who were between September 1999 and May 2006 
referred to the Academic Medical Center in Amsterdam, the Netherlands, were eligible 
for the study. We included 148 patients diagnosed with acute proximal DVT and 179 
patients in whom DVT was objectively excluded (controls) in the present study. DVT 
was diagnosed with compression ultrasound. DVT was ruled out in patients with a low 
pretest probability as assessed by the Wells score in combination with a negative D-dimer 
test and in patients with a negative serial compression ultrasound. In addition, controls 
did not have a history of previous venous thromboembolism, and controls with alternative 
diagnoses that may be associated with activation of coagulation (thrombophlebitis, calf 
vein thrombosis, calf muscle vein thrombosis, venous insufficiency, erysipelas, baker’s 
cyst, and muscle bleeding) were excluded from the study. Patients with DVT were selected 
regardless of the presence of thrombophilia or provoking comorbidities. All patients gave 
written informed consent, and collection of blood was approved by the Medical Ethical 
Committee of the Academic Medical Center, Amsterdam, the Netherlands.  
Blood collection and plasma preparation
Blood was drawn into 3.2% sodium citrate (9:1, v/v) prior to the initiation of anticoagulant 
treatment. Platelet-poor plasma was obtained by double centrifugation at 1500 g for 15 
min at room temperature. Plasma was aliquoted and stored at -80°C until use.
Plasma FVII and FVIIa levels
The plasma FVII and FVIIa levels were measured using in-house developed assays 
as described earlier [20]. Briefly, plasma levels of FVII and FVIIa were determined 
using a semi-automated ELISA on a Tecan Freedom EVO robot (Tecan, Männedorf, 
Switzerland). A sheep anti-FVII antibody (1 µg/ml; Stago, Leiden, the Netherlands) or 
a llama-derived antibody fragment directed against FVIIa (2 µg/ml) was immobilised on 
a 384-well plate (Thermo Fisher Scientific Inc., Waltham MA, USA) at 4°C overnight. 
After blocking, diluted plasma samples were added to the plate and incubated on a shaker 
set at 180 rpm for 2 h at room temperature. Bound FVII was detected using horseradish 
peroxidase (HRP)-labeled sheep anti-FVII antibody (0.5 µg/ml; Affinity Biologicals, 
Ancaster, Canada). FVIIa was detected using a chicken anti-FVII (0.16 µg/ml; Abcam, 
Cambridge, UK) antibody followed by a HRP-labeled donkey anti-chicken antibody 
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(2.2 µg/ml; Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA). 
Subsequently, a chemiluminescent substrate (SuperSignal West Pico Chemiluminescent 
Substrate, Thermo Fisher Scientific Inc., Waltham MA, USA) was added, and after 60 
min the luminescence was measured using a Spectramax reader (Molecular Devices, MDS 
Analytical Technologies, Sunnyvale, CA, USA). The luminescence values of the plasma 
samples were translated into FVII or FVIIa levels by using an 8 point calibration curve 
of pooled normal plasma or recombinant FVIIa (NovoSeven, Novo Nordisk, Bagsvaerd, 
Denmark). The intra-assay and interassay coefficients of variation of the ELISA were: 
<10% (n = 40) for FVIIa and <8% for FVII (n = 40). The FVII and FVIIa levels were 
determined in 144 (FVII) and 148 (FVIIa) patients diagnosed with acute DVT and 
in 174 (FVII) and 177 (FVIIa) controls as insufficient plasma was available for some 
patients. 
Plasma FVIIa-antithrombin complex levels
The plasma FVIIa-antithrombin (AT) complex levels were measured using an in-house 
developed assay, adapted from the previously described assay to measure FVIIa levels. In 
short, after diluted samples were added to plates coated with a llama-derived antibody 
fragment directed against FVIIa (2 µg/ml), FVIIa-AT complexes were detected with 
0.5 µg/ml HRP-labeled sheep anti-human antithrombin (Affinity Biologicals, Ancaster, 
Canada). The assay was calibrated using a standard, which was generated by incubating 
recombinant FVIIa and human AT (Enzyme Research laboratories, South Bend, IN, 
USA) in the presence of TF (Innovin, Siemens Healthcare Diagnostics, Marburg, 
Germany) and fondaparinux (Arixtra, GlaxoSmithKline, Zeist, the Netherlands) for 
1 h at 37°C. The standard was diluted in FVII-deficient plasma (Precision Biologic Inc., 
Dartmouth, NS, USA) to obtain a 15-point calibration curve. The plasma FVIIa-AT 
complex levels were determined in 145 patients diagnosed with acute DVT, and in 176 
controls as insufficient plasma was available for some patients.
Statistical analysis
The FVII, FVIIa and FVIIa-AT levels in patients diagnosed with acute DVT and in the 
control group are shown as median values. We present differences between median values 
with corresponding 95% bootstrap confidence interval (CI). The associations between 
plasma levels of FVII or FVIIa and the presence of DVT were analysed by means of 
logistic regression analysis and are expressed as odds ratios (ORs) with corresponding 
95% CIs. Levels were grouped into quartiles based on the distribution among controls. 
The lowest quartile of FVII and the highest quartile of FVIIa were taken as the reference 
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group. The influence of potential confounders (age, sex, smoking status, malignancy, 
paralysis, paresis or recent plaster immobilization of the lower extremities, recently 
bedridden >3 days and/or major surgery within 4 weeks and hospitalization <6 months) 
on the association between plasma levels of FVII or FVIIa and DVT were analysed by 
means of multivariable logistic regression models. For the analyses, we used the software 
package R (version 3.1.1, R Foundation for Statistical Computing, Vienna, Austria) and 
IBM SPSS Statistics, PC (release 20, IBM, New York, USA).
Results and discussion 
Table 1 shows the characteristics of the patients diagnosed with acute DVT (n = 148) and 
patients in whom this diagnosis was excluded (n = 179, controls). Established risk factors 
for DVT were present more frequently in patients compared with controls.
Antigen levels of FVII and FVIIa in patients and controls are shown in Figure 1. FVII 
levels were comparable between patients and controls (Figure 1A). Median FVII levels 
were 109.8% (interquartile range [IQR] 86.0-153.2) in patients compared to 102.2% 
(IQR 76.1-141.7) in controls (a difference of 7.6%, 95% CI -4.6-20.2). 
FVIIa levels were substantially lower in patients compared to controls (Figure 1B). 
Median FVIIa levels were 50.2 ng/ml (IQR 25.2-86.1) in patients compared to 96.6 ng/
ml (IQR 69.9-168.9) in controls (a difference of 46.4 ng/ml, 95% CI 29.6-69.7).
Figure 1 Plasma levels of FVII antigen (A) or FVIIa antigen (B) in patients diagnosed with DVT 
or in the control group. Horizontal lines indicate median values. 
High levels of FVII were associated with a slightly increased risk for the presence of a 
DVT as shown in table 2. Individuals with FVII levels in the upper quartile had a 1.6-
fold increased risk (OR 1.6, 95% CI 0.8-3.1) for the presence of a DVT compared with 
individuals with FVII levels in the lowest quartile, and this risk did not change after 
adjustment for potential confounders.
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Table 1 Characteristics of Study Population.*
n (acute DVT/ 
controls)†
Acute DVT Controls  
(no DVT)
Mean age, y (range) 148/175 58 (19-90) 59 (19-100)
Male sex, n (%) 148/179 69 (47) 81 (45)
Body mass index, kg/m2 (SD) 146/172 26.6 (4.5) 28.6 (5.8)
Malignancy (on treatment/
recently treated), n (%)
141/172 24 (16) 22 (12)
Smoking, n (%)  148/177 39 (26) 39 (22)
Paralysis, paresis, or recent 
plaster immobilization lower 
extremities, n (%)
147/173 15 (10) 14 (8)
Recent immobilization  
(bedridden >3 days, major 
surgery <4 wk), n (%)
147/171 26 (18) 13 (7)
History of recent trauma  
(<60 d), n (%)
146/172 18 (12) 20 (11)
Hospitalization (<6 mo), n (%) 147/173 35 (24) 24 (13)
Oral contraceptives use,  
n females (%)
148/179 21 (14) 11 (6)
* Parameters are at time of blood sample collection. † Some variables were not available for 
all patients. Indicated are the numbers of patients for whom values were available. 
Low levels of FVIIa were associated with an increased risk for the presence of a DVT. 
Individuals with FVIIa levels in the lowest quartile had a more than 5-fold increased 
risk for the presence of a DVT (OR 5.5, 95% CI 2.8-10.6) compared with individuals 
with FVIIa levels in the highest quartile, and this risk did not substantially change after 
adjustment for potential confounders.
We found substantially decreased levels of FVIIa in patients in the acute phase of a DVT, 
which at first glance is paradoxical since it has been well established that there is active 
coagulation activation in such patients, as indicated by, for example, elevated levels of 
prothrombin fragment 1+2 and thrombin-antithrombin (TAT) complexes [21-23]. 
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We thus hypothesized to find elevated levels of FVIIa as a result of TF-mediated FVII 
to FVIIa conversion similar to previous findings on elevated FVIIa levels in sepsis and 
acute coronary syndromes [20,24]. The decreased FVIIa levels in patients, however, may 
indicate ongoing consumption of FVIIa.
We detected FVIIa-antithrombin complexes only in a minority of patients (n = 16, 
11%) and controls (n = 58, 33%). In those individuals in whom detectable levels of the 
FVIIa-AT complex were detected, levels were substantially higher in patients compared to 
controls. Median levels were 25.8 pM (IQR 9.1-54.9) in patients compared to 7.2 (IQR 
5.3-12.5) in controls (a difference of 18.6 pM, 95% CI 1.9-38.5). 
Our results, thus, do not exclude that active, TF-mediated FVII to FVIIa conversion takes 
place in patients during an acute venous thrombosis, as it may be that the FVIIa does 
drive coagulation activation but is rapidly inhibited and/or cleared by the AT-dependent 
mechanisms as increased FVIIa-AT complex levels were measured in these patients. In 
line with our results, Spiezia et al. also showed reduced levels of FVIIa in patients with 
acute venous thrombosis [25]. In contradiction to our results, this study showed that 
FVIIa-AT complex levels were decreased in these patients, which led these authors to 
conclude that in acute thrombosis the formation of TF-FVIIa-FXa-TFPI complexes 
may be the preferred inhibitory route, which results in decreased levels of FVIIa-AT 
complexes. Although we find elevated levels of FVIIa-AT complexes in patients compared 
to controls, the proportion of controls in whom detectable levels were measured was more 
than 3-fold higher compared to patients with detectable levels. This latter finding may 
be in line with the findings of Spiezia et al. Notably, another study with a similar design 
found no difference in FVIIa levels between patients and controls [26]. 
The combined results of our study suggest the TF pathway to be activated during venous 
thrombus formation. Since levels of FVII, TFPI and FXI are, and levels of FXII are 
not associated with the risk of venous thrombosis, a role of FXIIa-mediated activation 
of coagulation in the development of venous thrombosis appears minor. We therefore 
hypothesize that initiation of venous thrombus formation proceeds via the TF pathway. 
Subsequent thrombin-mediated activation of FXI appears vital in propagation of venous 
thrombus formation given the profound antithrombotic effect of a pharmacological 
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